The government has given the green light to using blood transfusions including platelets created from artificially derived stem cells to treat patients with intractable diseases.
A team from Kyoto University plans to begin a transfusion trial using induced pluripotent stem cells (iPS cells) that will be the fourth clinical test using iPS cells approved by the health ministry and the first to use blood components.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.